

RESEARCH ARTICLE

# Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial Cells

Amber Cardani<sup>1,2</sup>, Adam Boulton<sup>3</sup>, Taeg S. Kim<sup>1,4</sup>, Thomas J. Braciale<sup>1,2,4\*</sup>

**1** Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia, United States of America, **2** Department of Microbiology, University of Virginia, Charlottesville, Virginia, United States of America, **3** Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, United States of America, **4** Department of Pathology, University of Virginia, Charlottesville, Virginia, United States of America

\* [tjb2r@virginia.edu](mailto:tjb2r@virginia.edu)



 OPEN ACCESS

**Citation:** Cardani A, Boulton A, Kim TS, Braciale TJ (2017) Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial Cells. *PLoS Pathog* 13(1): e1006140. doi:10.1371/journal.ppat.1006140

**Editor:** Paul G. Thomas, St. Jude Children's Research Hospital, UNITED STATES

**Received:** August 15, 2016

**Accepted:** December 19, 2016

**Published:** January 13, 2017

**Copyright:** © 2017 Cardani et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** The RNAseq data used in this manuscript are available at the GEO with accession number GSE93085.

**Funding:** This work was supported by NIH grant 4R01AI015608-35 and NIH/NIGMS T32 GM007055 T32 GM007055. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Abstract

The Influenza A virus (IAV) is a major human pathogen that produces significant morbidity and mortality. To explore the contribution of alveolar macrophages (AlvMΦs) in regulating the severity of IAV infection we employed a murine model in which the Core Binding Factor Beta gene is conditionally disrupted in myeloid cells. These mice exhibit a selective deficiency in AlvMΦs. Following IAV infection these AlvMΦ deficient mice developed severe diffuse alveolar damage, lethal respiratory compromise, and consequent lethality. Lethal injury in these mice resulted from increased infection of their Type-1 Alveolar Epithelial Cells (T1AECs) and the subsequent elimination of the infected T1AECs by the adaptive immune T cell response. Further analysis indicated AlvMΦ-mediated suppression of the cysteinyl leukotriene (cysLT) pathway genes in T1AECs *in vivo* and *in vitro*. Inhibition of the cysLT pathway enzymes in a T1AECs cell line reduced the susceptibility of T1AECs to IAV infection, suggesting that AlvMΦ-mediated suppression of this pathway contributes to the resistance of T1AECs to IAV infection. Furthermore, inhibition of the cysLT pathway enzymes, as well as blockade of the cysteinyl leukotriene receptors in the AlvMΦ deficient mice reduced the susceptibility of their T1AECs to IAV infection and protected these mice from lethal infection. These results suggest that AlvMΦs may utilize a previously unappreciated mechanism to protect T1AECs against IAV infection, and thereby reduce the severity of infection. The findings further suggest that the cysLT pathway and the receptors for cysLT metabolites represent potential therapeutic targets in severe IAV infection.

## Author Summary

A primary feature of lethal influenza infection is viral pneumonia. Influenza viral pneumonia is caused by the direct infection of alveolar epithelial cells, which subsequently causes extensive alveolar inflammation and injury. Clinically this pathology manifests as diffuse alveolar damage leading to acute respiratory distress syndrome. As alveolar

macrophages are positioned in the alveoli, they are the ideally localized to be a first-line of defense against alveolar invading pathogens, such as influenza. To explore the contribution of alveolar macrophages to the development of lethal influenza pneumonia, we generated a novel mouse model with a selective deficiency in alveolar macrophages. As a result of the alveolar macrophage deficiency, these mice developed severe diffuse alveolar damage and lethal respiratory compromise after influenza infection. Lethal injury resulted from increased infection of type-1 alveolar epithelial cells, and the elimination of these infected cells by effector T cells. Further analysis indicated that in order to render type 1 cells resistant to influenza infection, alveolar macrophages suppress leukotrieneD4 production and autocrine-signaling in type 1 cells. These results suggest that alveolar macrophages play a previously unappreciated role in protecting type 1 alveolar epithelial cells against IAV infection, and thus the severity of infection.

## Introduction

The Influenza A virus (IAV) is a major human pathogen. In the United States alone, IAV infections are associated with more than 20,000 deaths and 300,000 hospitalizations annually [1]. IAV is a negative sense RNA virus that is transmitted by aerosol and fomites [2]. Upon inhalation, IAV primarily infects and replicates in respiratory epithelial cells. After completion of the replication cycle the newly formed virions are released apically from the infected cells back into the pulmonary airspaces, allowing the virions to reach the more distal cells of the respiratory tract as the infection evolves [3].

Eventually the infectious IAV virions reach the terminal airways, which are lined by type 1 and type 2 AECs (T1 and T2AEC). As T1AECs are responsible for gas exchange, extensive infection and the subsequent elimination of these cells can lead to severe pulmonary compromise [4,5]. In the murine model of IAV infection, one of the prominent differences between infection with highly pathogenic IAV strains and strains producing limited morbidity and mortality, is the degree to which T1AECs become infected and are subsequently eliminated [6,7]. Furthermore, diffuse alveolar damage (DAD), defined by the presence of fibrin deposition and alveolar hyaline membrane formation, as well as viral infection of alveolar epithelial cells are frequently found in autopsies of severe clinical IAV infection [4,8]. Taken together, these data strongly suggest that the degree of alveolar epithelium infection by IAV, and the extent of the resulting injury, is one the many crucial regulators of the outcome of IAV infection.

Recently, several reports have implicated the lung resident alveolar macrophages (AlvMΦs) as critical modulators of IAV disease severity and the development of lethal pulmonary injury [9–12]. However, the mechanism(s) by which AlvMΦs influence the outcome of IAV infection has yet to be clearly determined, although an inability to clear cellular debris and exudates has been implicated. AlvMΦs are classically thought to be negative immune regulators and thereby inhibit inflammatory responses to harmless inhaled antigens [13]. Conversely, their location within the terminal airways also suggests that AlvMΦs are one of the first innate immune cell types to encounter any inhaled potentially harmful microbes. Therefore, AlvMΦs are also believed to be an important initiator of the inflammatory response during bacterial infections, making them an important first line of defense against lower respiratory tract infection [14]. In the clinical setting, AlvMΦ dysfunction has been observed in multiple disease settings including asthma, allergies, chronic obstructive pulmonary disease, pulmonary fibrosis,

smoking related lung disease, and, in the complete absence of Alveolar Macrophages (AlvMΦs), the development of pulmonary alveolar proteinosis [15–19].

While screening mice that had genes linked to myeloid lineage development knocked out specifically in myeloid cells, we identified a mouse model in which there was a cellular deficiency selectively in the AlvMΦ compartment. In this mouse model the expression of Core Binding Factor Beta (CBFβ), which regulates the activity of the Runx family of transcription factors essential for myelopoiesis, is selectively knocked out in myeloid cells expressing Lysozyme M (LysM). This was accomplished by crossing CBFβ floxed mice with mice that express Cre recombinase driven off of the LysM promoter (CBFβ<sup>ALysM</sup>) [20, 21]. As a consequence of CBFβ gene disruption, these mice exhibit a deficiency in AlvMΦs without detectable consequences in the number or function of other LysM expressing cells in the lung and spleen, thereby allowing us to better define and elucidate the mechanisms by which AlvMΦs regulate the outcome of influenza infection.

We report here that the AlvMΦ deficient CBFβ<sup>ALysM</sup> mice are highly susceptible to lethal IAV infection. With the exception of their markedly reduced number of AlvMΦs, CBFβ<sup>ALysM</sup> mice exhibit no deficiency in innate or adaptive immune cells in the lungs prior to or following IAV infection. The AlvMΦ deficiency did result in a marked increase in susceptibility of T1AECs to IAV infection, resulting in the development of DAD and lethal injury following infection. Indeed, a precipitous decline in respiratory function and development of lethal injury in these AlvMΦ deficient mice was associated with the onset of the adaptive immune response in the infected lungs, and immune mediated elimination of the infected T1AECs.

We further demonstrate that the AlvMΦ-conferred T1AEC resistance to IAV infection was associated with the suppression of the genes for enzymes involved in the 5-lipoxygenase (5-LOX) to cysteinyl leukotriene (cysLT) pathway in T1AECs from infected lungs. Consistent with a role for AlvMΦs in regulating the susceptibility of T1AECs to IAV infection through control of the cysLT pathway, blockade/knockdown of cysLT pathway enzymes in T1AECs *in vitro* or antagonism of the cysLT pathway and the cysteinyl leukotriene receptor 1 *in vivo* reduced the susceptibility of T1AECs to IAV infection and rendered the AlvMΦ deficient CBFβ<sup>ALysM</sup> mice resistant to lethal IAV infection.


## Results

### Characterization of the Conditional CBFβ Deficient Mice

To assess the impact of disruption of the CBFβ gene in the myeloid lineage we examined the outcome of intranasal (i.n.) infection of CBFβ<sup>ALysM</sup> mice and wild type (WT) control CBFβ<sup>fl/fl</sup> littermates with a sublethal dose (0.1LD<sub>50</sub>) of the mouse adapted Influenza A strain A/PR/8 [H1N1]. As expected, infected WT mice survived and recovered from this inoculum dose (Fig 1a). However, CBFβ<sup>ALysM</sup> mice exhibited markedly reduced survival (> 85% mortality) following infection (Fig 1a) suggesting that expression of CBFβ in one or more cell types of the myeloid lineage was critical for recovery from IAV infection.

Since several cell types of myeloid origin are affected by LysM driven Cre-mediated inactivation of the CBFβ gene, we employed the ROSA26 reporter mouse system, which allowed us to identify the cell type(s) responsive to LysM-Cre by Cre driven YFP expression. As Table 1 indicates, both before and after infection, efficient recombination (YFP expression) was primarily restricted to neutrophils and AlvMΦs, each of which displayed greater than 80% LysM-Cre driven recombination. By contrast, inflammatory mononuclear cells and respiratory dendritic cells were only modestly YFP<sup>+</sup> (~ 20% or less) (Table 1) (Gating strategy S1 Fig).

The above reporter mouse analysis suggested that inactivation of the CBFβ gene by LysM-Cre would primarily affect the neutrophil and/or AlvMΦs lineages. However, published



**Fig 1. Alveolar macrophage deficient CBFβ<sup>ΔLysM</sup> mice exhibit enhanced mortality after influenza infection.** WT and CBFβ<sup>ΔLysM</sup> mice were infected i.n. with a 0.1LD<sub>50</sub> of A/PR/8. a) Survival (left) and weight loss (right) (with surviving CBFβ<sup>ΔLysM</sup> mice removed) out to day 20 PI. b) Representative flow plots and total numbers of AlVMΦs (left) and CD11b<sup>+</sup> AlVMΦs (right) in the BAL fluid at day 0 PI. c) Total protein detected in the BAL at the indicated days PI. d) Total number of AlVMΦs in the BAL and lungs at the indicated days PI. e) Total number of neutrophils in the lung and their f) percent with cell surface CD107a (first panel) and CD11b MFI (second panel) at the indicated days PI. g) Total numbers of lung interstitial macrophages and h) respiratory

dendritic cells at day 0 PI. i) Total numbers of inflammatory mononuclear cells and j) percentage that are Ly6C<sup>+</sup> in the lungs at the indicated days PI. Data were pooled from a minimum of 3 experiments with a total of 5–12 infected mice per genotype at each indicate time point. Error bars are standard error mean. Statistical analysis is a two-tailed non-paired students t test for single time points or 2-way ANOVA when multiple time points are present. \* indicates P < .05, \*\* for P < .001 and \*\*\* for P < .001.

doi:10.1371/journal.ppat.1006140.g001

findings indicate that the RUNX TFs are essential early during neutrophil development, but are down regulated just as LysM expression is upregulated [22]. Therefore, we did not expect pulmonary neutrophil accumulation and function to be significantly impacted by the CBFβ deletion. By contrast, examination of the CD45<sup>+</sup> cells in the bronchial alveolar lavage (BAL) fluid and lungs of naïve mice revealed markedly diminished numbers of Alveolar Macrophages (AlvMΦs) (CD45<sup>+</sup>, CD11c<sup>+</sup>, Siglec F<sup>+</sup> cells) in the CBFβ<sup>ΔLysM</sup> mice compared to their WT littermate controls (70%-80% reduction in the BAL and 50%-75% in the lung) (Fig 1b). In contrast to WT AlvMΦs, which are classically defined as CD11b<sup>-</sup>, the majority of the small number of AlvMΦs in the CBFβ<sup>ΔLysM</sup> BAL fluid and lungs were CD11b<sup>+</sup>, however they still maintained typical macrophage morphology (Fig 1b and S2a Fig). Immature AlvMΦs are initially CD11b<sup>+</sup>, but down regulate CD11b as they mature/differentiate. Therefore, since CBFβ expression supports myeloid lineage development, the small number of CD11b<sup>+</sup> AlvMΦs could represent cells at an early/intermediary stage in AlvMΦ development/ differentiation [23, 24]. Of note, the residual AlvMΦs in naive CBFβ<sup>ΔLysM</sup> mice were sufficient to prevent the development of alveolar proteinosis as determined by BAL protein concentration and lung histology/morphology (Fig 1c and S2b Fig). After IAV infection there was a transient decrease in the number of AlvMΦs in the BAL of WT mice that began to recover by day 7 PI and progressively increased out to day 11 PI. In contrast, the AlvMΦ deficit in the CBFβ<sup>ΔLysM</sup> mice became even more pronounced over time with few AlvMΦs (CD11b<sup>-</sup> or CD11b<sup>+</sup>) detectable at day 7 PI and beyond (Fig 1d).

As expected, we observed no difference between WT and CBFβ<sup>ΔLysM</sup> mice in their lung and BAL accumulation of neutrophils (CD45<sup>+</sup>, Siglec F<sup>-</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup> cells) before and during IAV infection (Fig 1e and S2d Fig). We also detected no difference in cell surface expression of CD107a (a marker of degranulation) or in the magnitude of CD11b expression (which is elevated on activated neutrophils) on pulmonary neutrophils following IAV infection in WT and CBFβ<sup>ΔLysM</sup> mice (Fig 1f) [25]. In summary, these data suggest that, as expected, neutrophil infiltration and function during IAV infection is unaffected in CBFβ<sup>ΔLysM</sup> mice.

There was also no deficit in the total number of pulmonary interstitial macrophages (CD45<sup>+</sup>, Siglec F<sup>-</sup>, CD11b<sup>+</sup>, F4/80<sup>+</sup> cells) (Fig 1g) or respiratory dendritic cells (CD45<sup>+</sup>, CD11c<sup>+</sup>, MHCII<sup>+</sup>, Siglec F<sup>-</sup>, B220<sup>-</sup> cells, either CD103<sup>+</sup> or CD11b<sup>+</sup>) (Fig 1h) in WT and

**Table 1. Pulmonary YFP expression in LysM-Cre x ROSA26 reporter mice prior to and during IAV infection.**

Cell Type	Highest Rate of YFP Expression From Day 0-7PI
CD45-	0%
T cells	0%
NK cells	0%
Eos	0%
rDC	13%
AlvMΦs	85%
Neutrophils	84%
IMNCs	22%

doi:10.1371/journal.ppat.1006140.t001



CBF $\beta^{\Delta\text{LysM}}$  mice. LysM driven Cre recombination activity was also detected in a minor fraction of cells making up the heterogeneous population of inflammatory mononuclear cells (IMNCs) (Table 1). The absolute number of IMNCs (CD45<sup>+</sup>, CD11b<sup>+</sup>, Siglec F<sup>-</sup>, Ly6G<sup>-</sup> cells) (Fig 1i and S2e Fig) and the frequency of IMNCs that express Ly6C (Fig 1j) before or during IAV infection were likewise unaffected in CBF $\beta^{\Delta\text{LysM}}$  mice. As there was no difference in IMNC infiltration between wild type and CBF $\beta^{\Delta\text{LysM}}$  mice, CCR2 expression by the mononuclear cells was not further evaluated. Interestingly, we also saw no difference in splenic macrophages, neutrophils, IMNCs and DCs in CBF $\beta^{\Delta\text{LysM}}$  and WT mice (S2c Fig). These data suggest that the disruption of CBF $\beta$  in the CBF $\beta^{\Delta\text{LysM}}$  mice had only a minimal, if any, effect on the development and effector response of these pulmonary mononuclear cell subsets and the innate immune response to IAV infection.


### Characterization of Virus Clearance and the Adaptive Immune Response in IAV Infected CBF $\beta^{\Delta\text{LysM}}$ Mice

In previous reports acute depletion of Alveolar Macrophages (AlvM $\Phi$ s) prior to IAV infection was shown to result in enhanced virus titers and impaired adaptive T cell responses [9, 11, 12]. In order to determine if the loss of AlvM $\Phi$ s in the CBF $\beta^{\Delta\text{LysM}}$  mice resulted in uncontrolled virus replication, or had any impact on the IAV adaptive response, we next evaluated virus replication/clearance and the adaptive response in WT and CBF $\beta^{\Delta\text{LysM}}$  mice. The CBF $\beta^{\Delta\text{LysM}}$  mice succumbed to infection between days 8 and 15 PI (Fig 1a), which are following the characteristic onset of the adaptive immune response and concomitant virus clearance as observed in WT mice [26]. The tempo of IAV replication and clearance in the lungs was comparable for WT and CBF $\beta^{\Delta\text{LysM}}$  mice as determined by BAL fluid virus titers (Fig 2a). It is noteworthy that infectious virus was no longer detectable by day 11 PI, when infected CBF $\beta^{\Delta\text{LysM}}$  mice succumbed to infection. Infectious virus clearance was also confirmed by the analysis of viral gene expression in whole lung homogenates of WT and CBF $\beta^{\Delta\text{LysM}}$  mice (Fig 2b), which was comparable, except for a statistically non-significant trend toward a slight delay in clearance of the spliced IAV M2 gene mRNA in CBF $\beta^{\Delta\text{LysM}}$  mice (Fig 2b) [26].

The above findings indicate that virus clearance was normal in the CBF $\beta^{\Delta\text{LysM}}$  mice, suggesting that the adaptive immune response to IAV was not affected. Indeed, following infection, BAL IAV-specific IgG antibodies (Fig 2c), total CD4 T cells (Fig 2d) and IAV-specific CD8 T cells (Fig 2e) in the CBF $\beta^{\Delta\text{LysM}}$  mice were comparable to WT mice. Furthermore, kinetics of effector T cell derived cytokines IFN $\gamma$ , IL-10, and TNF were similar between CBF $\beta^{\Delta\text{LysM}}$  mice and their WT littermates (Fig 2f). Consistent with previously published observations we were unable to detect Th2 or Th17 T cell responses (Fig 2g) in the lungs of CBF $\beta^{\Delta\text{LysM}}$  or WT mice. A multiplex analysis of 30 cytokines and chemokines (listed in the Methods section) in the BAL fluid at days 0, 2, 4, 7, and 11 PI also gave comparable values for WT and CBF $\beta^{\Delta\text{LysM}}$  mice, except for a modest elevation in CCL2 (days 7 and 11 PI) and CXCL9 (day 11 PI) in infected CBF $\beta^{\Delta\text{LysM}}$  mice. Cumulatively, these data indicate that the AlvM $\Phi$  deficiency has no demonstrable effect on the establishment of the anti-IAV adaptive immune responses and IAV clearance, or on the function and properties of the innate immune cells involved in the induction of adaptive immune responses, particularly rDCs.

### IAV Infection in AlvM $\Phi$ Deficient Mice Results in Severe Respiratory Insufficiency and Marked Diffuse Alveolar Damage

The above results indicated that the quality and magnitude of the innate and adaptive host response, as well as the efficiency of virus clearance, in the IAV infected lungs were comparable between WT and CBF $\beta^{\Delta\text{LysM}}$  mice. We did however observe a significant increase in



**Fig 2. Virus clearance and adaptive immune responses in CBFβ<sup>ΔLysM</sup> mice.** WT and CBFβ<sup>ΔLysM</sup> mice were infected i. n. with a 0.1LD<sub>50</sub> dose of A/PR/8. Kinetics of virus replication and clearance as determined a) in BAL fluid by TCID<sub>50</sub> units (dashed line is the lower limit of detection) and b) by qRT-PCR for the spliced IAV M2 gene at the indicated days PI. c) Representative levels of IAV specific IgG antibodies in the BAL fluid at day 11 PI. d) Total number of CD4 T cells and e) CD8 T cells positive for the IAV PA antigen tetramer in the lungs at the indicated days PI. Kinetics of BAL f) IFN<sub>γ</sub>, IL-10 and TNF g) IL-4 and IL-17. For IAV specific antibodies, data is representative of 2 experiments for a total of 5 WT and 6

CBFβ<sup>ΔLysM</sup> mice. For all other data, data were pooled from a minimum of 3 experiments with a total of 4–9 mice per genotype at each indicate time point. Error bars are standard error mean. A 2-way ANOVA was used for statistical analysis. \* indicates P < .05, \*\* for P < .001 and \*\*\* for P < .001. L.D. is limit of detection, NS is not significant, N.D. is not detectable.

doi:10.1371/journal.ppat.1006140.g002

erythrocyte extravasation into the airways/BAL fluid of CBFβ<sup>ΔLysM</sup> mice when analyzed at day 7 and 11 PI. In order to directly quantify the extent of vascular leak in the infected lungs, we examined the accumulation of Evans Blue dye in the airways of WT and CBFβ<sup>ΔLysM</sup> mice one hour after intravenous administration. While vascular leak was comparable in WT and CBFβ<sup>ΔLysM</sup> mice on day 4 PI, by day 7 PI CBFβ<sup>ΔLysM</sup> mice had markedly elevated Evans Blue dye accumulation in their airways (Fig 3a). These findings raised the possibility that there was substantial pulmonary capillary leak in the IAV infected CBFβ<sup>ΔLysM</sup> mice, suggesting extensive alveolar damage was occurring at the time of onset of the adaptive immune response.

To assess whether the elevated vascular leak in the lungs of infected CBFβ<sup>ΔLysM</sup> mice had any consequences on lung structure, we compared histopathologic changes in the lungs of infected WT and CBFβ<sup>ΔLysM</sup> mice (Fig 3b). At day 12 PI both WT and CBFβ<sup>ΔLysM</sup> mice displayed extensive interstitial inflammation and edema characteristic of severe IAV infection. However, the CBFβ<sup>ΔLysM</sup> mice additionally had extensive intra-alveolar fibrin deposition, hyaline membrane formation and loss of alveolar wall integrity, reflecting histologic features characteristics of diffuse alveolar damage (Fig 3b). These findings suggest that the Alveolar Macrophage (AlvMΦ) deficiency in CBFβ<sup>ΔLysM</sup> mice is linked to the development of enhanced alveolar injury following IAV infection.


A hallmark of enhanced alveolar injury with diffuse alveolar damage during severe IAV infection is compromised respiratory function, most notably diminished O<sub>2</sub> exchange resulting in hypoxemia. When we analyzed blood O<sub>2</sub> saturation in WT and CBFβ<sup>ΔLysM</sup> mice following IAV infection, we observed that out to day 5 PI, O<sub>2</sub> saturation was comparable in both WT and CBFβ<sup>ΔLysM</sup> mice (Fig 3c). However at day 6 PI, corresponding with the onset of the IAV specific adaptive immune response in the lungs, there was a precipitous drop in O<sub>2</sub> saturation in the CBFβ<sup>ΔLysM</sup> mice, which resulted in progressive severe hypoxemia on subsequent days analyzed (Fig 3c).

It is noteworthy that there was only a modest initial decline in blood O<sub>2</sub> saturation at day 4–5 PI in both WT and CBFβ<sup>ΔLysM</sup> mice in spite of extensive IAV replication in the infected lungs at these early times (Fig 2a and 2b). The precipitous decline in O<sub>2</sub> saturation coinciding with the onset of adaptive immune response raised the possibility that adaptive immune-mediated clearance of IAV infected epithelial cells was responsible for the rapid decline in O<sub>2</sub> saturation CBFβ<sup>ΔLysM</sup> mice. Indeed, the simultaneous depletion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells at day 3 PI, thereby inhibiting the subsequent infiltration of these cells into the lungs, prevented the decline in O<sub>2</sub> saturation at day 7 PI in CBFβ<sup>ΔLysM</sup> mice (Fig 3d). By contrast, depletion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in infected WT mice had only a modest effect on O<sub>2</sub> saturation (Fig 3d). Consistent with a role for the adaptive immune T cell response to IAV in the development of respiratory compromise, infected untreated adaptive immune deficient RAG KO mice also displayed only a modest decline in blood O<sub>2</sub> saturation out to day 7 PI (Fig 3d).

### AlvMΦs Regulate the Susceptibility of Type 1 Alveolar Epithelial Cells to IAV Infection

The accumulated evidence demonstrating alveolar pulmonary vascular leak, histologic changes reflecting severe alveolar damage, and compromised pulmonary function (Fig 3a–3d) suggested that AECs were the likely target of the effector T cells in the CBFβ<sup>ΔLysM</sup> mice. In order to





**Fig 3. AlvM $\Phi$ s regulate the susceptibility of type 1 alveolar epithelial cells to IAV infection.** WT and CBF $\beta^{\Delta LysM}$  mice were infected i.n. with a 0.1LD<sub>50</sub> dose of a-c) 0.1LD<sub>50</sub> of A/PR/8 or d-g) NS1-GFP A/PR/8. a) At the indicated days PI Evans Blue dye leak into the airspace was quantified. b) Representative H&E section images from day 12 PI IAV infected WT and CBF $\beta^{\Delta LysM}$ . c) Percent blood oxygen saturation at the indicated days PI. d) Day 7 PI blood oxygen saturation after i.p. injection of CD4 and CD8 depleting antibodies at day 3 PI. Percent of (left) and total numbers of (right) infected e) T1AECs and f) conducting airway epithelial cells at day 4 & 7 PI. g) AlvM $\Phi$ s were transferred i.n. at day -1 PI and (left) the percent of T1AECs that were infected at day 4 PI was determined, as well as, (right) CBF $\beta^{\Delta LysM}$  survival out to day 20 PI (n = 4 CBF $\beta^{\Delta LysM}$  mice

treated with AlvMΦs). h-j) WT mice were irradiated and given either congenic CD45.1 WT bone marrow, CD45.2 CBFβ<sup>ΔLysM</sup> bone marrow, or a mixture of 90% CBFβ<sup>ΔLysM</sup> and 10% WT bone marrow (Mix). h) Seven weeks after reconstitution, the origin of the pulmonary myeloid cells in the mixed bone marrow chimera and i) the total number of AlvMΦs in the BAL was quantified. j) The percent of T1AECs that were infected (GFP<sup>+</sup>) at day 4 and 7 PI. Data were pooled from a minimum of 3 experiments with a total of 4–11 mice per genotype at each indicate time point. Error bars are standard error mean. For statistical analysis a two-tailed non-paired students t test, 1-way ANOVA or 2-way ANOVA was used where appropriate. \* indicates P < .05, \*\* for P < .001 and \*\*\* for P < .001; NS is not significant.

doi:10.1371/journal.ppat.1006140.g003

determine if the T cell mediated alveolar injury in CBFβ<sup>ΔLysM</sup> mice was related to the extent of AEC infection, we infected WT and CBFβ<sup>ΔLysM</sup> mice with the reporter A/PR/8–NS1–GFP strain, which allows for the identification of infected cells by GFP expression [27]. Pulmonary epithelial cells were identified as CD45<sup>+</sup>, CD31<sup>+</sup> and EpCAM<sup>+</sup>. Following published protocols, T1AECs were distinguished by podoplanin/T1α expression [28–31] and T2AECs were identified by cell surface MHCII expression, which we confirmed co-localized with intracellular pro-Surfactant Protein C staining in T2AECs from naïve lungs [31–35] (S3a and S3b Fig). CD45<sup>+</sup>, CD31<sup>+</sup> and EpCAM<sup>+</sup> cells that were negative for AEC lineage markers T1α or MHCII were grouped as bronchial/bronchiolar epithelial cells (referred to here as conducting airway epithelial cells) [35] (S3a and S3b Fig). (However, it should be noted that because of modest MHCII expression, the ratio of conducting airway cells to T2AECs might not be fully representative.) As Fig 3e demonstrates, the frequency of IAV infected T1AECs from CBFβ<sup>ΔLysM</sup> mice was significantly elevated compared to the AlvMΦ sufficient WT mice at both day 4 & 7 PI. Importantly, while the frequency of infected T1AECs from the CBFβ<sup>ΔLysM</sup> mice remained high at day 7 PI, the total number of infected T1AECs did decrease from day 4 to day 7 PI (Fig 3e), consistent with T cell mediated elimination of these virally infected cells at the latter time point.

In contrast, the susceptibility of the conducting airway cells and T2AECs from CBFβ<sup>ΔLysM</sup> mice to IAV infection was increased at day 4 PI, but returned to WT levels by day 7 PI, before the death of the CBFβ<sup>ΔLysM</sup> mice (Fig 3f and S3c Fig). Again, the total number of infected pulmonary epithelial cells decreased with the onset of the adaptive immune response in both AlvMΦ deficient CBFβ<sup>ΔLysM</sup> mice and AlvMΦ sufficient WT mice. Given the three-fold increase in infection of T1AECs in CBFβ<sup>ΔLysM</sup> mice, the two-fold increase in T2AEC infection by IAV was not unexpected (Fig 3e and S3c Fig). However, while both conducting and T2AEC infection rates returned to WT levels by day 7PI, the rate of T1AEC infection selectively remained high throughout infection in the AlvMΦ-deficient CBFβ<sup>ΔLysM</sup> mice (Fig 3e and 3f and S3c Fig).

To determine if restoring AlvMΦs to CBFβ<sup>ΔLysM</sup> mice would likewise restore resistance of T1AECs to IAV infection we employed two strategies. Firstly, we adoptively transferred 5x10<sup>5</sup> WT AlvMΦs into CBFβ<sup>ΔLysM</sup> mice by the i.n. route, one day prior to IAV infection. Transfer of AlvMΦs into CBFβ<sup>ΔLysM</sup> mice rescued the resistance of their T1AECs to IAV infection, but had no impact on the susceptibility of T1AECs from WT mice (Fig 3g left panel). Importantly, this transfer of AlvMΦs into CBFβ<sup>ΔLysM</sup> mice, which conferred resistance of T1AECs to infection, also rescued CBFβ<sup>ΔLysM</sup> mice resistance to lethality after IAV infection (Fig 3g right panels).


Secondly, we constructed mixed bone marrow chimeric mice in which irradiated WT (CD45.2<sup>+</sup>) mice were reconstituted with either CD45.1<sup>+</sup> WT bone marrow, CD45.2<sup>+</sup> CBFβ<sup>ΔLysM</sup> bone marrow, or a mixture of 90% CBFβ<sup>ΔLysM</sup> and 10% WT bone marrow (Mix). Since the CBFβ<sup>ΔLysM</sup> donor bone marrow would not be able to fully regenerate AlvMΦs in the irradiated recipients, a 10% WT bone marrow supplement was employed in the 90:10 mixed chimeras to selectively reconstitute the AlvMΦ compartment with WT cells, while all other bone marrow derived cell types would be primarily CBFβ<sup>ΔLysM</sup> bone marrow derived.

Seven weeks after reconstitution, Alveolar Macrophages (AlvMΦs) in irradiated WT bone marrow reconstituted recipients were exclusively of donor bone marrow origin (S3d Fig). In the 90:10 mixed bone marrow recipients, the AlvMΦs were the only myeloid cells in the lungs that were derived from WT bone marrow at a frequency greater than 10% (Fig 3h), reflecting a partial restoration of AlvMΦ numbers (Fig 3i). Following IAV infection, the T1AECs from the mixed bone marrow chimeric mice with the partial AlvMΦs rescue demonstrated an enhanced resistance to IAV infection, which was comparable to the control irradiated WT bone marrow chimeras (Fig 3j).

Lastly, since neutrophils, like AlvMΦs, strongly express LysM (Table 1) we evaluated the impact of acute neutrophil depletion (by administration of the neutrophil depleting antibody IA8) on the susceptibility of T1AECs to infection. We observed no effect of neutrophil depletion on T1AEC susceptibility to IAV infection (S3e Fig). In sum these data further support the concept that  $CBF\beta^{ALysM}$  mice have a selective quantitative deficiency in AlvMΦs, and that this deficit in AlvMΦs results in enhanced susceptibility of T1AECs cells to IAV infection.

### AlvMΦs Act Early in IAV Infection to Regulate the Susceptibility of T1AECs

Since, even in WT mice, AlvMΦ numbers are diminished by day 4 PI, (Fig 1d), we sought to determine when AlvMΦs conferred resistance of T1AECs to IAV infection. To do so, we employed a mouse model in which the diphtheria toxin (DTx) receptor is expressed under control of the CD11c promoter (CD11c-DTxR), allowing for the depletion of CD11c<sup>+</sup> cells, including AlvMΦs, following DTx administration. DTx was administered prior to or up to 48hours following IAV infection. The susceptibility of T1AECs to IAV infection was evaluated at day 4 PI, prior to the onset of the adaptive immune response in the lungs, and therefore, before the impact of DTx administration on the elimination of rDCs would manifest. Similar to T1AEC from  $CBF\beta^{ALysM}$  mice, T1AECs from CD11c-DTxR mice displayed enhanced susceptibility to IAV infection at day 4 PI when diphtheria toxin was administered i.n. on day -1 or day 1 PI (Fig 4a). On the other hand, when AlvMΦs were eliminated at day 2 PI, T1AEC susceptibility to IAV infection was comparable to T1AECs from DTx treated WT control mice (Fig 4a). These findings suggested that AlvMΦs function between days 1 and 2 PI to confer



**Fig 4. AlvMΦs function early in infection to confer resistance of type 1 alveolar epithelial cell to IAV infection.** a) CD11c-DTr+ and WT control littermates were given 40ng of DTx i.n. at the indicated time points pre or post infection with NS1-GFP A/PR/8. The percentage of infected T1AECs was quantified at day 4PI. b) WT mice were infected i.n. with a 0.1LD50 of A/PR/8 and BAL AlvMΦs were isolated and stained for cell surface IAV HA antigen and intracellular IAV NP antigen at the indicated time points. Data were pooled from a minimum of 3 experiments with a total of 4–6 mice per genotype at each indicate time point. Flow plots are representative from 5 mice. Error bars are standard error mean. For statistical analysis 2-way ANOVA test were used. \* indicates  $P < .05$ , \*\* for  $P < .001$  and \*\*\* for  $P < .001$ .

doi:10.1371/journal.ppat.1006140.g004

resistance of T1AECs to IAV infection. This is a time when there is minimal recruitment of other CD45<sup>+</sup> cell types into the parenchyma or airways, and therefore, when Alveolar Macrophages (AlvMΦs) are the predominant CD45<sup>+</sup> cell type in the airways.

To directly determine whether AlvMΦs were exposed to IAV at the time they were conferring resistance of T1AECs to infection, we evaluated the kinetics of AlvMΦ infection. As Fig 4b demonstrates, while viral genes were not detected in AlvMΦs isolated from the BAL prior to or on day 1 PI, cell surface HA and intracellular NP proteins were readily detectable by day 2 PI. This finding suggested that the regulation of T1AEC susceptibility by AlvMΦs was associated with AlvMΦ exposure to IAV.

### AlvMΦs Confer Resistance to IAV Infection by Regulating Expression of a Leukotriene Pathway in T1AEC


Type I and III Interferons (IFNs) are important mediators of resistance to IAV infection and AlvMΦs have been implicated as one source of IFNs during infection [36]. Both Type I and Type III IFNs were detected at comparable levels in the BAL fluid of the AlvMΦ deficient CBFβ<sup>ΔlysM</sup> and WT mice days 0–2 PI (Fig 5a). This is during the time frame in which AlvMΦs were demonstrated to confer resistance of T1AEC to IAV infection. Furthermore, there was no difference in the expression of representative IFN stimulated genes (ISGs) in whole lungs or sorted T1AECs isolated from CBFβ<sup>ΔlysM</sup> and WT mice at day 2 PI (Fig 5b and 5c). Taken together, these findings suggested that, while IFNs are essential in controlling IAV infection, AlvMΦs were not utilizing IFNs to protect T1AEC from IAV infection.

To gain insight as to why T1AECs in the presence of AlvMΦs were more resistant to IAV infection, we carried out transcriptomic profiling (RNAseq) on T1AECs isolated from the lungs of the AlvMΦ deficient CBFβ<sup>ΔlysM</sup> mice and AlvMΦ sufficient WT mice at day 2 PI, after AlvMΦ mediated resistance to infection had been conferred (Fig 4a).

RNAseq revealed that no genes were preferentially down regulated in the day 2 T1AECs from CBFβ<sup>ΔlysM</sup> mice, but a number of genes were preferentially upregulated. Pathway analysis on the genes over expressed in the CBFβ<sup>ΔlysM</sup> T1AECs using the NIH DAVID database revealed that nine of the genes were enzymes/co-factors involved in the arachidonic acid metabolism pathway (Fig 5d) [37, 38]. Four of the genes encode molecules involved in the cytochrome P450 (CYP4F18, CYP4F16), Thromboxane (Tbxas1) and 15-lipoxygenase (ALOX15) pathways of arachidonic acid metabolism (Fig 5e). The other five genes (ALOX5, ALOX5ap, Cot11, GGT1 and DPEP2) encode enzymes or co-factors involved in the 5-lipoxygenase (5-LOX) cysteinyl leukotriene (cysLT) pathway that generates the cysLT metabolites: leukotriene C4 (LTC4), leukotriene D4 (LTD4) and leukotriene E4 (LTE4) (Fig 5e). Of note, the gene encoding the sixth enzyme in this pathway, leukotriene C4 synthase (LTC4S), also trended at greater than a two-fold enhancement in expression in the CBFβ<sup>ΔlysM</sup> T1AECs, but lacked statistical significance.

Due to the current lack of mouse models that would allow us to selectively probe T1AECs *in vivo*, as well as the inability to sustain T1AECs in culture *ex vivo*, we utilized the recently created and characterized T1AEC cell line of C57Bl/6 origin, LET1 cells, to explore any link between AlvMΦ mediated resistance of T1AECs to IAV and the expression of these arachidonic acid pathway enzymes in T1AECs [28]. We first confirmed published results that podoplanin positive LET1 cells can be infected with A/PR/8 NS1-GFP IAV as determined by GFP expression (Fig 5f) [28]. Consistent with our *in vivo* findings, primary AlvMΦs co-cultured directly with LET1 cells (or separated by a membrane barrier in transwell cultures) significantly reduced the infection of LET1 cells by IAV (Fig 5f). Co-culture of LET1 cells with splenic CD11c<sup>+</sup> cells resulted in only a minimal increase in resistance of LET1 cells to





**Fig 5. AlvM $\Phi$ s suppress T1AEC expression of arachidonic acid metabolism pathway genes.** a-e) WT and CBF $\beta^{\Delta LysM}$  mice were infected i.n. with a 0.1LD<sub>50</sub> of A/PR/8. a) IFN $\alpha$  and IFN $\lambda$  protein in the BAL fluid prior to and during IAV infection. Representative interferon stimulated genes b) detected by qRT-PCR of whole lung homogenates c) and detected by RNAseq on sorted T1AECs at day 2 PI. d) Genes identified as over expressed in T1AECs from CBF $\beta^{\Delta LysM}$  mice at day 2PI were grouped by pathway analysis. e) Arachidonic acid metabolism genes differentially expressed as determined by RNAseq. f) Percent of infected (GFP+) LET1 cells at 24hours post infection when cultured with media vehicle, AlvM $\Phi$ s directly, AlvM $\Phi$ s in transwell inserts or directly with splenic CD11c+ cells. g) Expression of the corresponding arachidonic acid metabolism pathway genes by qRT-PCR at 8 hours post infection in LET1 cells cultured alone or with AlvM $\Phi$ s. a) BAL fluid was isolated from 4–10 mice per genotype at each indicate time point. c-d) 2–3 samples of pooled T1AECs from day 2 PI mice were used for RNAseq. For *in vitro* analyses, data were pooled from or is representative of a minimum of 3 experiments. Error bars are standard error mean. Statistical analysis is a) 2-way ANOVA, c) a linear regression analysis or f) 1-way ANOVA. \* indicates P < .05, \*\* for P < .001 and \*\*\* for P < .001. N.S. is not significant.

doi:10.1371/journal.ppat.1006140.g005

infection, suggesting that the effect of the AlvM $\Phi$ s on the LET1 cells was not due to a simple change in the MOI of the T1AECs in culture. We next utilized the LET1 and AlvM $\Phi$  co-culture system to determine if AlvM $\Phi$  mediated resistance to IAV was linked to the transcriptional inhibition of these arachidonic acid pathway enzymes in T1AECs. As Fig 5g demonstrates, consistent with our findings *in vivo*, the expression of genes encoding the arachidonic acid metabolism enzymes were reduced in infected LET1 cells co-cultured with AlvM $\Phi$ s.

To determine if the activity of one or more of these arachidonic acid metabolism enzymes facilitates IAV infection of T1AECs, we examined the impact of small molecule inhibitors targeting these enzymes on the susceptibility of LET1 cells to IAV infection. Inhibition of thromboxane synthase enzymatic activity in LET1 cells with the inhibitor Ozagrel had minimal or no




impact on IAV infection of the LET1 cells (Fig 6a). On the other hand, inhibition of enzymes along the cytochrome P450 F and A family pathway (by the small molecule inhibitor HET0016) resulted in a modest, statistically significant impact on IAV infection of LET1 cells (Fig 6a). Furthermore, inhibition of the activity of the 5-LOX pathway enzyme ALOX5 by Zileuton also produced a similar significant reduction in LET1 cell susceptibility to IAV infection (Fig 6a). We next examined the impact of inhibition of the activity the two enzymes downstream of ALOX5 in the cysLT pathway that were likewise upregulated in T1AECs from the Alveolar Macrophage (AlvMΦ) deficient mice. Inhibition of the activity of gamma glutamyl transferase-1 (GGT1) (which converts the metabolite LTC4 to LTD4) in LET1 cells alone with the drug Acivicin markedly reduced the susceptibility of LET1 cells to IAV infection. Conversely, inhibition of the enzyme DPEP2 (which converts LTD4 to the less biologically active metabolite LTE4) with the inhibitor Cilastatin had no effect on T1AEC susceptibility to infection (Fig 6a), suggesting that LTD4, but not LTE4, may regulated the susceptibility of T1AECs to IAV infection.

AlvMΦs, which render T1AECs resistant to IAV infection *in vivo* and *in vitro*, also reduced GGT1 expression *in vivo* and *in vitro* (Fig 5b and 5c). Inhibition of GGT1 enzymatic activity in T1AECs by Acivicin, likewise, decreased T1AEC susceptibility to IAV infection. Because Acivicin is not a selective GGT1 inhibitor, we next determined if knockdown of GGT1 expression in LET1 cells would also reduce their susceptibility to infection. As Fig 6b shows, compared to cells expressing control-scrambled shRNA, partial knockdown of GGT1 expression by GGT1 shRNA lentivirus treatment (Fig 6b left panel) also reduced the susceptibility of shRNA treated LET1 cells to IAV infection (Fig 6b right panel).

Although the interaction of AlvMΦs with LET1 cells *in vitro* recapitulated the effect of AlvMΦs on the susceptibility of T1AECs *in vivo*, this *in vitro* interaction likely does not reflect the full impact of AlvMΦs on T1AECs during IAV infection *in vivo*. Therefore, in order to determine if LTD4 production impacted the susceptibility of T1AECs *in vivo*, we evaluated the effect of Acivicin administration to WT and CBFβ<sup>ALysM</sup> mice on the susceptibility of T1AEC. Acivicin was administration at 5 and 29 hours PI i.n. to inhibit early LTD4 production. These time points are prior to the large influx of CD45<sup>+</sup> inflammatory immune cells into the lung, which can also be a significant source of cysLT metabolites [26]. *In vivo* Acivicin treatment markedly reduced the susceptibility of T1AEC from CBFβ<sup>ALysM</sup> mice to IAV infection. Of note, Acivicin had only a minimal effect on the susceptibility of T1AECs from the AlvMΦ sufficient WT mice (Fig 6c). This latter finding suggests that the ability of Acivicin to reduce the susceptibility of T1AECs to infection is not due to nonspecific suppression of IAV infection.

The above evidence supported a link between the activity of the 5-LOX/cysLT metabolic pathway in T1AEC and their susceptibility to IAV infection. This is of interest as elevated levels of LTE4, the stable terminal metabolite of the cysLT pathway, has been reported to correlate with increased severity of IAV infection in both humans and mice [39]. LTD4 signals by engaging the cell surface Cysteinyl LT receptors (CysLT1 and/or CysLT2). The aforementioned RNAseq analysis revealed that at day 2 PI T1AECs express CysLT1 with twenty-two-fold higher FPKM (Fragments per Kilobase Mapped) than CysLT2 (Fig 6d). This is of particular interest as CysLT1 has higher affinity for LTD4 than CysLT2.

In order to explore the possibility that LTD4 engagement of CysLT1 on T1AECs was responsible for the enhanced susceptibility of T1AECs in the AlvMΦ deficient CBFβ<sup>ALysM</sup> mice, we administered the CysLT1 antagonist Zafirlukast to these mice. As Fig 6e demonstrates, like Acivicin, i.p. administration of Zafirlukast on days 0–3 PI, markedly reduced T1AEC susceptibility to IAV infection in CBFβ<sup>ALysM</sup> mice. Consistent with this data, Zafirlukast administration also rendered the treated CBFβ<sup>ALysM</sup> mice resistant to lethal IAV infection (Fig 6f). These data are consistent with the concept that AlvMΦs act, at least in part, to



**Fig 6. Inhibition of the 5-LOX pathway or blockade CysLT1 renders T1AECs resistant to IAV infection.** a) Infectivity of LET1 cells infected with NS1-GFP A/PR/8 in the presence of the specified treatment. b) Lentivirus shRNA knockdown of GGT1 (left panel) and the impact LET1 cell infectivity (right). c) WT and CBFβ<sup>ΔLysM</sup> mice were infected i.n. with NS1-GFP A/PR/8 and treated i.n. with 2.5mg/kg of Acivicin or vehicle at 5 and 29hours post infection. Infection of T1AECs (left) and conducting airway epithelial cells (right) was analyzed at day 4 PI. d) Expression of the CysLT1 and CysLT2 receptors in sorted T1AECs from WT and CBFβ<sup>ΔLysM</sup> at day 2PI as determined by RNAseq. e) Day 4 T1AEC infectivity in WT and CBFβ<sup>ΔLysM</sup> mice that were infected i.n. with NS1-GFP A/PR/8 and. f) CBFβ<sup>ΔLysM</sup> mice that were infected i.n. with 0.1LD<sub>50</sub> of A/PR/8 and treated i.p. with 10mg/kg of Zafirlukast or vehicle every 24 hours starting at 5 hours PI until day 3 PI. g) Relative fluorescence of pHrodo Red labeled transferrin that has been taken up via the endocytic route by LET1 cells in the presence of different treatments. For *in vitro* analyses, data were pooled from, or is representative of, a minimum of 3 experiments with each dot representing 2-pooled wells from a 24well plate. c and e) data was pooled 3 experiments for a total of 4–6 mice for each treatment and genotype. Error bars are standard error mean. Statistical analysis is either a 2-way ANOVA, 1-way ANOVA, or a two-tailed non-paired students t test. \* indicates P < .05, \*\* for P < .001 and \*\*\* for P < .001.

doi:10.1371/journal.ppat.1006140.g006

suppress the susceptibility of T1AECs to infection by inhibiting cysLT pathway, possibly in T1AECs, which in-turn suppresses LTD4 signaling through CysLT1 on T1AEC.

The above findings suggest that engagement of CysLT1 on T1AECs enhances the susceptibility of these cells to infection by IAV. It has previously been reported that the initial enzyme in the Arachidonic Acid Metabolic Pathway, Phospholipase D, may facilitate IAV uptake [40]. Furthermore, key signaling molecules activated downstream of LTD4's engagement of CysLT1 (ROCK1 and RAC) have been demonstrated to facilitate endocytic uptake of IAV [41, 42]. Therefore, we next sought to determine if Alveolar Macrophages (AlvMΦs), which inhibit the arachidonic acid

metabolism and cysLT pathway, also modulate endocytosis in T1AEC by evaluating receptor-dependent endocytic uptake of transferrin. As Fig 6g demonstrates, IAV-infected Alveolar Macrophages (AlvMΦs), but not naïve AlvMΦs, decreased LET1 cell receptor-mediated clathrin-dependent endocytosis of transferrin that was labeled with the pH-sensitive dye pHrodo Red. Similarly, inhibition of GGT1 activity with Acivicin also decreased LET1 cell endocytic uptake of pHrodo Red labeled transferrin (Fig 6g). These findings are consistent with our data demonstrating AlvMΦ-mediated suppression of the cysLT pathway and protection of T1AECs from IAV infection *in vitro* and *in vivo*.

## Discussion

In this report we have evaluated the contribution of AlvMΦs to the host response in experimental IAV infection. We observed that mice with a genetic deficiency selectively in AlvMΦs (CBFβ<sup>ALysM</sup> mice) are highly susceptible to IAV infection. This deficiency in AlvMΦs resulted in increased susceptibility of T1AECs to IAV infection that could be rescued by transferring WT AlvMΦs into the CBFβ<sup>ALysM</sup> mice, suggesting that AlvMΦs are important mediators of T1AEC resistance to IAV infection. Along with increased numbers of infected T1AEC, the IAV infected AlvMΦ deficient mice also exhibit severely compromised pulmonary function and morphologic evidence of diffuse alveolar damage, which are compatible with severe lethal IAV pneumonia. While Type I and Type III IFNs are essential for respiratory epithelial cell resistance to IAV infection (including T1AEC), AlvMΦ-mediated protection of T1AECs was IFN-independent. Rather, our data strongly implicates that AlvMΦ-mediated transcriptional suppression of the cysLT pathway enzymes in T1AECs is one possible mechanism that mediates T1AEC resistance to IAV infection. Consistent with this resistance mechanism, inhibition of the cysLT pathway enzymes, in particular GGT1 reduced the susceptibility of T1AECs in CBFβ<sup>ALysM</sup> mice to infection, as did antagonism of the cysLT receptor CysLT1.

Earlier reports evaluating the host response to IAV infection demonstrated a critical role for AlvMΦs in modulating the severity and outcome of IAV infection [9–13, 19]. While AlvMΦ phagocytosis of IAV particles, cellular debris and clearance of edema fluid undoubtedly contributes to AlvMΦ-mediated protection during IAV infection, a direct link between AlvMΦ function and the development of lethal pneumonia was not established in these reports. While it is currently not possible to directly assay cysLT metabolite production exclusively by T1AEC *in vivo* or *ex vivo*, to probe T1AEC CysLT receptor activity *in vivo* or *ex vivo*, or to disrupt this arachidonic acid metabolic pathway specifically in T1AECs *in vivo*, our results strongly suggest that there is a link between AlvMΦ-mediated resistance of T1AECs to IAV infection and AlvMΦ-mediated suppression of the expression of genes evolved in the cysLT pathway in T1AECs. This was evident both *in vivo*, where T1AEC from infected AlvMΦ deficient mice exhibited elevated expression of genes encoding cysLT pathway enzymes, as well as *in vitro*, where co-culture of T1AEC with AlvMΦs during IAV infection reduced both the expression of cysLT pathway genes and IAV infection. Additional support for a role of the cysLT pathway enzymes in regulating the efficiency of T1AEC IAV infection came from the effect of inhibiting 5-LOX (by the inhibitor Zileuton) and GGT1 (by the inhibitor Acivicin) specifically in LET1 cells. Even more compelling was the finding that treatment of infected CBFβ<sup>ALysM</sup> mice and WT mice with Acivicin within the first two-days post infection significantly reduced the frequency of infected T1AEC in the AlvMΦ deficient CBFβ<sup>ALysM</sup> mice, but had minimal effect on infection of T1AEC from infected WT mice. While our findings most likely reflect the impact of a quantitative deficiency in the number of AlvMΦs in the lungs of the CBFβ<sup>ALysM</sup> mice, we cannot formally exclude the possibility that there is a subtle change in the function of the few residual AlvMΦs detected in the lungs. Likewise, we also cannot

formally exclude that alterations in the function of other LysM expressing cell types lacking CBF $\beta$  could also affect the susceptibility of T1AECs to infection, and therefore the outcome of infection in the CBF $\beta^{\Delta\text{LysM}}$  mice. However, findings on the effect of AlvM $\Phi$  transfer into CBF $\beta^{\Delta\text{LysM}}$  mice, as well as the effect of acute depletion of AlvM $\Phi$  in the CD11c-DTR model, strongly implicate AlvM $\Phi$ s as having a primary role and mediating resistance of T1AECs to infection.

The timing of AlvM $\Phi$ -mediated protection, along with the timing of cysLT gene activation and the brief, early timeframe in which Acivicin treatment worked have two important implications. First is that *in vivo* T1AECs are protected at a time point when AlvM $\Phi$ s would be the predominant, if not exclusive, cell type in the alveoli to detect the infection and confer resistance to T1AEC. Therefore, it is formally possible that AlvM $\Phi$ s are not the only CD45<sup>+</sup> cell type capable of providing protection to T1AECs, and that it is their proximity to the AECs at this early time point that allows them to confer protection. Second, many of the CD45<sup>+</sup> cell types that have been classically established as the cysLT producers have yet to substantially accumulate in the lungs or reach the airways by day 2 PI, which, once again, is when our data, particularly on Acivicin administration, strongly suggests that the cysLT metabolites are acting on the T1AECs to enhance their susceptibility to IAV infection. The finding that T1AECs may produce cysLTs is further supported by a growing body of literature demonstrating that, while initially *in vitro* data indicated that only myeloid cells express 5-LOX and therefore produce cysLTs [43], *in vivo* non-hematopoietic cell types as diverse as neurons, epithelial cells and endothelial cells are capable of expressing 5-LOX and producing cysLTs [44–50].

Methylation of the ALOX5 gene promoter has been reported in cell lines where the cysLT pathway is inactive. Therefore, methylation of ALOX5 has been suggested as the mechanism of gene silencing that accounts for the lack of 5-LOX expression and cysLT production by these cell types [48–50]. Since AlvM $\Phi$ s prevent the upregulation of the cysLT pathway genes in T1AECs, AlvM $\Phi$ s may confer resistance of T1AECs to infection by maintaining the ALOX5 promoter in a methylated state. As far as we are aware, there is minimal information concerning mechanisms to account for suppression, particularly transcriptional suppression of the cysLT pathway beyond methylation of the ALOX5 gene. We therefore attempted to identify the suppressive factor by screen the BAL fluid for inflammatory mediators that maybe differentially represented in the CBF $\beta^{\Delta\text{LysM}}$  mice at day 2 PI when the 5-LOX and the cysLT pathway is suppressed by AlvM $\Phi$ s. However, as noted above (Results), a 30-plex-cytokine/chemokine survey revealed no detectable differences in the inflammatory mediators present in the BAL at days 0 and 2 PI.

Activation of the cysLT pathway results in the synthesis of the cysLT metabolites LTC<sub>4</sub>, LTD<sub>4</sub> and LTE<sub>4</sub>. A role for LTD<sub>4</sub> engagement of CysLT1 on T1AECs was supported by the evidence that blockade of CysLT1 through Zafirlukast administration markedly reduced T1AEC susceptibility to IAV infection and prevented IAV associated mortality in CBF $\beta^{\Delta\text{LysM}}$  mice. These findings raise the possibility that T1AEC production of the CysLT metabolite LTD<sub>4</sub> may support cellular uptake or replication of IAV in T1AEC by signaling through cysLT receptors displayed by T1AEC.

Engagement of CysLT1, a G-protein coupled receptor, by LTD<sub>4</sub> results in the mobilization of intracellular calcium. IAV has been reported to utilize calcium dependent activation of the ROCK-1 and RAC-1 signaling pathways in cells to facilitate IAV virion uptake and internalization [41, 42]. Constant with this work, we found that IAV-infected AlvM $\Phi$ s were able to suppress LET1 cell endocytic uptake of transferrin. Signaling through CysLT receptors can also result in calcium-dependent activation of PI-3 kinase and CAM kinase in cells, which in turn enhances IAV gene expression in cells infected with certain IAV strains [41]. Thus the enhanced susceptibility of T1AEC to IAV infection in the absence of AlvM $\Phi$ s may reflect both

increased efficiency of virus uptake and the extent of virus replication as a result of CysLT1 engagement.

While we observed an increase in the frequency and absolute number of infected T1AEC in  $\text{CBF}\beta^{\Delta\text{LysM}}$  mice, overall lung virus titers in these animals only trended towards a slight enhancement and were only modestly elevated compared to lung virus titers in WT mice. This was in contrast to earlier reports in other mouse models [12] where an  $\text{AlvM}\Phi$  deficiency resulted in elevated pulmonary virus titers. This discrepancy is perhaps not unexpected as the deficiency in  $\text{AlvM}\Phi$ s numbers is quantitative in our model, and T1AECs, while capable of productive IAV infection, are not as efficient in virion production as conducting airway epithelial cells [28]. Therefore, the 3-fold increase in infected T1AECs in the  $\text{AlvM}\Phi$  deficient mice may not significantly impact the level of detectable virions in the infected lungs. We also demonstrate that the enhanced mortality of  $\text{CBF}\beta^{\Delta\text{LysM}}$  mice after IAV infection is likely not a direct result of virus mediated destruction of the increased number of IAV infected cells. Rather, our results suggest that the increased number of infected T1AEC rendered these cells more susceptible to adaptive-mediated elimination, and as a consequence, the development of lethal diffuse alveolar damage.

In conclusion, we have identified a novel role for  $\text{AlvM}\Phi$ s in modulating the severity of IAV infection by regulating the expression of the *cysLT* pathway in T1AECs and, as a consequence, the susceptibility of T1AECs to IAV infection. In addition to the mechanism proposed in this manuscript,  $\text{AlvM}\Phi$ s are likely to act through other IFN-dependent and—-independent mechanism to limit IAV severity. However, our findings raise the possibility that therapeutic strategies to limit the susceptibility of T1AECs to infection, including blockade or antagonism of CysLT receptor signaling, early in infection could limit the development and severity of lower respiratory tract IAV infection.

## Materials and Methods

### Ethics Statement

This study was carried out in strict accordance with the Animal Welfare Act (Public Law 91–579) and the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (OLAW/NIH, 2002). All animal experiments were performed in accordance with protocols approved by the University of Virginia Animal Care and Use Committee (ACUC; Protocol Number 2230) [26].

### Mice and Infection

All mice were bred and housed in a pathogen-free environment and used at 7–14 weeks of age for all experiments. NS1-GFP virus was a generous gift from the Adolfo Garcia-Sastre laboratory. Influenza A viruses PR8 (H1N1) and NS1-GFP [27] were grown in the allantoic cavity of day 10 chicken embryos as described previously [26]. Mice were infected with 250  $\text{EID}_{50}$  units of PR8 ( $0.1\text{LD}_{50}$ ), or  $10^5$   $\text{EID}_{50}$  NS1-GFP [26]. All infectious doses were administered i.n. in 50  $\mu\text{L}$  of serum-free Dulbecco's Modified Eagle Medium (Invitrogen) following ketamine and xylazine anesthesia. For i.n. transfer of cells, 500,000  $\text{AlvM}\Phi$ s were given in 50  $\mu\text{L}$  of serum-free Dulbecco's Modified Eagle Medium (Invitrogen) following ketamine and xylazine anesthesia. Irradiation and bone marrow transplantation mice were irradiated with 9.5 Gy and, within 24 hours, i.v. injected with RBC-lysed bone marrow cells ( $1-3 \times 10^6$ ) [26]. For  $\text{AlvM}\Phi$  depletion CD11c-DTr+ and CD11c-DTr- BALB/C littermates were given 40 ng of DTx i.n. following ketamine and xylazine anesthesia. Acivicin was diluted in serum-free Dulbecco's Modified Eagle Medium (Invitrogen) and 2.5 mg/kg was given i.n. in 50  $\mu\text{L}$  following ketamine



and xylazine anesthesia. 10mg/kg of Zafirlukast was given daily on days 0–3 PI by i.p. injection in 1mL of saline with 1%DMSO and 2% hydroxypropyl- $\beta$ - cyclodextrin (HPCD).

## Sample Preparation

Mice were euthanized via cervical dislocation. Lungs were then perfused with PBS via the heart. Lungs were enzymatically digested with Type II collagenase (37°C for 30 minutes; Worthington) for analysis of hematopoietic cells. For epithelial cell analysis lungs were inflated and digested with Dispase 2 (37°C for 30 minutes; Invitrogen). Digestion was followed by passage through a steel mesh screen to remove tissue fragments. Red blood cells in the cell suspensions were lysed using ammonium chloride. Cells were enumerated using a hemocytometer. Cells were re-suspended in FACS buffer containing PBS, 2% FBS, 10mM EDTA, and 0.01% sodium azide for Ab staining or MACS buffer containing PBS, 2% FBS, and 10 mM EDTA.

## Bronchoalveolar Lavage Fluid (Cytokine, Viral Titer and Anti-Influenza IgG)

We obtained BAL fluid by flushing the airways three times with a single inoculum of 500uL sterile PBS introduced via a trachea incision. BAL fluid cytokine content was determined using the Luminex 100 IS system maintained by the UVA Flow Cytometry Core. The 30-factors assayed were: Eotaxin, GM-CSF, IFN $\gamma$ , IL-1a, IL-1b, IL-2, IL-4, IL-3, IL-5, IL-6, IL-7, IL-9, IL-10, IL12p40, IL-12-70, LIF, IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1a, MIP-1b, M-CSF, MIP-2, MIG, RANTES, TNF. Viral titer was determined via endpoint dilution assay and expressed as tissue culture infectious dose<sub>50</sub> (TCID<sub>50</sub>) units as previously described [26]. We incubated MDCK cells (ATCC collection) with tenfold dilutions of BAL fluid in serum-free trypsin supplemented DMEM culture medium. After 3–4 day incubation at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>, culture supernatants were collected and mixed with a half- volume of 1% chicken red blood cells (University of Virginia Veterinary Facilities) to detect virus replication by hemagglutination. Detectable hemagglutination indicated virus replication was used as the calculate sample TCID50 values [26]. Influenza specific IgG antibodies in the airspaces were quantified by coating ELISA plates with A/PR/8 and incubating with tenfold dilutions of BAL fluid from influenza virus-infected mice. After washing, anti-mouse IgG was used to detect the amount of influenza specific IgG antibodies that were present in to BAL fluid at day 11 PI.

## Flow Cytometry Staining, Analysis, and Sorting

All FACS antibodies are purchased from BD Biosciences or eBioscience. The dilution of surface staining antibodies was 1 in 200 for 30 min at 4°C. After antibody staining, we examined cells using a six or eight-color FACS-Canto system (BD Biosciences) and the data were analyzed by FlowJo software (Treestar) and FMO or isotype controls were used to set gates. We characterized the epithelial cell types as follows: Conducting airways (CD45<sup>-</sup> CD31<sup>-</sup> T1 $\alpha$ <sup>-</sup> EpCAM<sup>+</sup> MHCII<sup>-</sup>) and T1AECs (CD45<sup>-</sup> CD31<sup>-</sup> T1 $\alpha$ <sup>+</sup> EpCAM<sup>+</sup>). Alveolar macrophages (AlvM $\Phi$ s) were isolated from whole lungs by MACS enrichment for cells expressing either CD11c or Siglec F according to manufactures protocol generating around a 90% pure AlvM $\Phi$  population. T1AEC sorting was done using a modified protocol for sorting cells from culture for RNAseq analysis [51]. Briefly, T1AECs were stained and sorted directly into Trizol LS from whole lung suspensions in the presence of RiboLock using the Becton Dickinson Influx Cell Sorter and DEPC treated 1XPBS.

## Quantitative Reverse-Transcription PCR

We isolated RNA from the lungs via Triazol (Invitrogen) and treated it with DNase I (Invitrogen). We used random primers (Invitrogen) and Superscript II (Invitrogen) to synthesize first-

strand complementary DNAs from equivalent amounts of RNA from each sample. We performed real-time RT-PCR in a 7000 Real-Time PCR System (Applied Biosystems) with SYBR Green PCR Master Mix (Applied Biosystems). Data were generated by the comparative threshold cycle ( $\Delta$ CT) method by normalizing to HPRT [26]. Forward and reverse primers amplifying are as follows, respectively:

**M2:**5'GAGGTCGAAACG CCT 3' & 5'CTGTTTCCTTTCGATATTCTTCCC3', **CYP4F18:**5'AGAGCCTGGTGC GAACCTT 3' & 5' TGGAATATGCGGATGACTGG 3', **CYP4F16:**5'GGAGTGGCTTCCTGGATTTT3' & 5'ATGCAGGGTCAACAATCCTC3', **TBXAS1:**5'AGGCTTCTGAAAGAGGTGGACCT3' & 5'TGAAATCACCATGTCCAGATAC3', **ALOX5:**5'ATGCCCTCCTACACTGTCAC3' & 5'CCACTCCATCCATCTATACT3', **ALOX5ap:**5'CTCCCA GATAGCCGACAAAG3' & 5'CAGAACTGCGTAGATGCGTA3', **COTL1:**5'GATGAGGGC AAACTTGGATCT3' & 5'GAGCAGATTACCAGCACTTCA3', **GGGT1:** 5'AGGAGAGAC GGTGACT3' & 5'GGCATAGGCAAACCGA3', **DPEP2:** 5'CTGACCTTTCTCTGCCACA3' & 5'GAATCTTCCTGATGACCTCCTG3'

### Evans Blue Dye

At the indicated day after infection with influenza, approx. 20mg/kg of Evans Blue dye in 500uL of 1X PBS was administered via the i.v. route. One hour later bronchoalveolar lavage fluid was obtained as described above. The absorbance of the dye at 620nm and 740nm was measured in BAL following removal of cells and debris and quantified with a standard curve obtained at the same time.

### Histology

Lungs were inflated with air using a sterile syringe and an intra-tracheal incision. The inflated lung was tied off and placed into Bouin's Fix Solution for at least three days. Fixed lungs were taken to UVA's Research Histology Core for Paraffin-embedding, slicing and Hematoxylin and Eosin staining.

### Measurement of Pulmonary Function

The MouseOx Pulse-oximeter (Starr Life Sciences, Oakmont PA) was used to measure blood oxygen saturation ( $SpO_2$ ). Prior to infection thigh hair of all mice was removed. Following ketamine and xylazine anesthesia, the thigh clamp was placed on the mouse and readings were taken on each mouse until it recovered from anesthesia. Oxygen saturation measurements were taken during recovery from anesthesia when oxygen saturation measurements had plateaued and only readings deemed successful by the software were used in our analysis.

### LET1 Cell Culture, Infection and Treatment

Let1 cells (a gift from Paul Thomas, St. Jude Hospital) were cultured and infected as previously described [28]. Briefly, 50,000 LET1 cells/ well were allowed adhere to wells of a 24 well tissue culture plate for 18hours in DMEM containing 10% FBS and antibiotics. Cell monolayers were then washed with OptiMEM to remove serum and non-adherent cells and then infected with A/PR/8 NS1-GFP in OptiMEM at an M.O.I. of ~100 to insure maximum infection of cells. Infection was carried out for 24hours, after which cells were liberated from the wells by manual manipulation. Two wells were pooled for each sample and live cells were analyzed by flow cytometry for T1 $\alpha$  and GFP expression. For co-culture of Let1 cells with Al $v$ M $\Phi$ s, 100,000 Al $v$ M $\Phi$ s were added directly onto the LET1 cells or into transwell inserts at the time of LET1 plating and the same infection protocol mentioned above was followed. All drugs were

introduced into the LET1 cell cultures at the time of infection at the specified concentrations, with or without DMSO, in OptiMEM. For stable knockdown of GGT1 in LET1 cells, lentiviral particles with control scrambled or GGT1 targeted shRNA were purchased from Santa Cruz Biotechnology (sc-35474-v) and used according to the manufactures protocol. Briefly, after an overnight incubation in 12 well plates, media containing Polybrene and 5 or 10uL of lentiviral particles was added. Cells were incubated overnight at 37°C and stable infection was selected for by maintaining the cells in media containing Puromycin dihydrochloride at 5ug/mL. For transferrin experiments, AlvMΦs were exposed to virus for 15 minutes at 4° and 20min at 37°. After virus was washed off the AlvMΦs were added to inserts and co-cultured with serum starved LET1 cells for one hour. pHrodo Red labeled transferrin (molecular probes) was then added to LET1 cells as per the manufacture's protocol for 10 minutes at 16° followed by a 30 minute incubation at 37°. Fluorescence intensity was determined by flow cytometry.

### RNAseq

Cells were sorted as described above, stored at -80°C and shipped to BGI Americas in trizol. There, RNA was isolated, enriched by poly-A-selection, and amplified. Following this samples were barcoded and sequenced using a 101PE lane on a HiSeq 2000 sequencer by Illumina.

Data were processed with the Tuxedo Suite software package [52]. Paired-reads were aligned and mapped to the GRCm38 mouse genome assembly, followed by differential expression analysis. Gene expression pathway analysis was carried out using the DAVID bioinformatics database [37, 38]. GEO accession number GSE93085.

### Statistical Analyses

Data are means ± SEM. We used non-paired Student's t test, one-way ANOVA or two-way ANOVA for statistical analyses. We considered all P values >0.05 not to be significant.

### Supporting Information

**S1 Fig. Gating strategy for innate immune cells.** a) CD45<sup>+</sup> cells were gated into b) Eosinophils CD11c<sup>-</sup> and Siglec F<sup>+</sup> or AlvMΦs as CD11c<sup>+</sup> and Siglec F<sup>+</sup>, which were further defined by CD11b expression. c) Siglec F<sup>-</sup> cells were then further characterized as neutrophils by CD11b<sup>+</sup> and Ly6G<sup>+</sup>, interstitial macrophages by CD11b<sup>+</sup> and F4/80<sup>+</sup>, or as IMNCs as CD11b<sup>+</sup>, F4/80<sup>-</sup> and Ly6G<sup>-</sup> with the latter then further being further characterized by the Ly6C expression. d) CD45<sup>+</sup> cells with limited FSC and SSC properties gated as CD11c<sup>+</sup>, MHCII<sup>high</sup>, and B220<sup>-</sup> were identified as rDCs, which are either CD11b<sup>+</sup> or CD103<sup>+</sup>. (TIFF)

**S2 Fig. Characterization of CBFβ<sup>ALysM</sup> mice.** Naïve WT and CBFβ<sup>ALysM</sup> mice a) BAL Cytospin and b) pulmonary histology images. Splenic c) macrophages, neutrophils, IMNCs and DCs were quantified in naïve WT and CBFβ<sup>ALysM</sup> mice. Kinetic analysis of BAL infiltrating d) neutrophils and c) IMNCs in A/PR/8 infected WT and CBFβ<sup>ALysM</sup> mice. (TIFF)

**S3 Fig. Pulmonary epithelial cell gating strategy.** a) Gating strategy of CD45<sup>-</sup>, CD31<sup>-</sup> cells for identifying T1AECs (CD45<sup>-</sup>, CD31<sup>-</sup>, EpCAM<sup>+</sup>, T1alpha<sup>+</sup>), conducting airway cells (CD45<sup>-</sup>, CD31<sup>-</sup>, EpCAM<sup>+</sup>, T1alpha<sup>-</sup> and MHCII<sup>-</sup>), and T2AECs (CD45<sup>-</sup>, CD31<sup>-</sup>EpCAM<sup>+</sup>, T1alpha<sup>-</sup> and MHCII<sup>+</sup>) (top panel) with validation of MHCII as a marker for T2AECs (bottom panel). b) GFP expression in T1AECs after infection with the NS1-GFP reporter A/PR/8 strain. GFP positivity was determined using T1AECs infected with the WT A/PR/8 strain that does not have a GFP reporter. c) Percent of (left) and total numbers of (right) infected T2AECs at day 4 & 7 PI.

d) NS1-GFP A/PR/8 infected WT mice received either control (IgG) or neutrophil depleting antibody (IA8) every 48hours by IP injection starting at day -1 PI. T1AEC infection was assessed on day 4 PI. For statistical analysis a two-tailed non-paired students t test (d) or 2-way ANOVA (c) was used where appropriate. \* indicates  $P < .05$ , \*\* for  $P < .001$  and \*\*\* for  $P < .001$ ; NS is not significant. (TIFF)

## Acknowledgments

We thank past and present members of the Braciale laboratory, particularly Mathew Hufford, Barbra Smalls and Martha Spano, for insightful discussions, technical assistance, and experimental suggestions. We would like to thank Evan Cardani for technical assistance. We also would like to thank Dr. Borna Mehrad and his lab for the use of their Mouse Pulse Oximeter, as well as the UVA flow and the UVA histology core. Lastly we would also like to thank Dr. Adolfo Garcia-Sastre for the NS1-GFP A/PR/8 virus and Dr. Paul Thomas for the LET1 cells.

## Author Contributions

**Conceptualization:** AC AB TJB.

**Data curation:** TJB.

**Formal analysis:** AC AB TJB.

**Funding acquisition:** TJB.

**Investigation:** AC AB TJB.

**Methodology:** AC AB TSK TJB.

**Project administration:** TJB.

**Resources:** AC AB TSK TJB.

**Supervision:** TJB.

**Validation:** AC TJB.

**Visualization:** AC AB TJB.

**Writing – original draft:** AC AB TJB.

**Writing – review & editing:** AC AB TJB.

## References

1. Thompson WW, Comanor L, Shay DK. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. *J Infect Dis.* 2006 Nov 1; 194: S82–S91. doi: [10.1086/507558](https://doi.org/10.1086/507558) PMID: [17163394](https://pubmed.ncbi.nlm.nih.gov/17163394/)
2. Hayden F, Croisier A. Transmission of avian influenza viruses to and between humans. *J Infect Dis.* 2005 Oct 15; 192 (8): 1311–4. doi: [10.1086/444399](https://doi.org/10.1086/444399) PMID: [16170745](https://pubmed.ncbi.nlm.nih.gov/16170745/)
3. Mora R, Rodriguez-Boulan E, Palese P, García-Sastre A. Apical budding of a recombinant influenza A virus expressing a hemagglutinin protein with a basolateral localization signal. *J Virol.* 2002 Apr; 76(7): 3544–53. doi: [10.1128/JVI.76.7.3544-3553.2002](https://doi.org/10.1128/JVI.76.7.3544-3553.2002) PMID: [11884578](https://pubmed.ncbi.nlm.nih.gov/11884578/)
4. Taubenberger JK, Morens DM. The pathology of influenza virus infections. *Annu Rev Pathol.* 2008 Aug; 3:499–522. doi: [10.1146/annurev.pathmechdis.3.121806.154316](https://doi.org/10.1146/annurev.pathmechdis.3.121806.154316) PMID: [18039138](https://pubmed.ncbi.nlm.nih.gov/18039138/)
5. Ward HE, Nicholas TE. Alveolar type I and type II cells. *Aust N Z J Med.* 1984 Oct; 14(5 Suppl 3): 731–734. PMID: [6598039](https://pubmed.ncbi.nlm.nih.gov/6598039/)

6. Sanders CJ, Vogel P, McClaren JL, Bajracharya R, Doherty PC, Thomas PG. Compromised respiratory function in lethal influenza infection is characterized by the depletion of type I alveolar epithelial cells beyond threshold levels. *Am J Physiol Lung Cell Mol Physiol*. 2013 Apr 1; 304 (7): L481–8. doi: [10.1152/ajplung.00343.2012](https://doi.org/10.1152/ajplung.00343.2012) PMID: [23355384](https://pubmed.ncbi.nlm.nih.gov/23355384/)
7. Brandes M, Klauschen F, Kuchen S, Germain RN. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. *Cell*. 2013 Jul 3; 154(1): 197–212. doi: [10.1016/j.cell.2013.06.013](https://doi.org/10.1016/j.cell.2013.06.013) PMID: [23827683](https://pubmed.ncbi.nlm.nih.gov/23827683/)
8. Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. *Am J Pathol*. 2008 May; 172(5): 1155–70. doi: [10.2353/ajpath.2008.070791](https://doi.org/10.2353/ajpath.2008.070791) PMID: [18403604](https://pubmed.ncbi.nlm.nih.gov/18403604/)
9. Laidlaw BJ, Decman V, Ali MA, Abt MC, Wolf AI, Monticelli LA, Mozdzanowska K, Angelosanto JM, Artis D, Erikson J, Wherry EJ. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. *PLoS Pathog*. 2013 Mar; 9(3): e1003207. doi: [10.1371/journal.ppat.1003207](https://doi.org/10.1371/journal.ppat.1003207) PMID: [23516357](https://pubmed.ncbi.nlm.nih.gov/23516357/)
10. Schneider C, Nobs SP, Heer AK, Kurrer M, Klinke G, van Rooijen N, Vogel J, Kopf M. Alveolar macrophages are essential for protection from respiratory failure and associated morbidity following influenza virus infection. *PLoS Pathog*. 2014 Apr 3; 10(4) e1004053. doi: [10.1371/journal.ppat.1004053](https://doi.org/10.1371/journal.ppat.1004053) PMID: [24699679](https://pubmed.ncbi.nlm.nih.gov/24699679/)
11. Kim HM, Lee YW, Lee KJ, Kim HS, Cho SW, van Rooijen N, Guan Y, Seo SH. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. *J Virol*. 2008 May; 82(9): 4265–74. doi: [10.1128/JVI.02602-07](https://doi.org/10.1128/JVI.02602-07) PMID: [18287245](https://pubmed.ncbi.nlm.nih.gov/18287245/)
12. Purnama C, Ng SL, Tetlak P, Setiagani YA, Kandasamy M, Baalasubramanian S, Karjalainen K, Ruedl C. Transient ablation of alveolar macrophages leads to massive pathology of influenza infection without affecting cellular adaptive immunity. *Eur J Immunol*. 2014 Jul; 44(7): 2003–12. doi: [10.1002/eji.201344359](https://doi.org/10.1002/eji.201344359) PMID: [24687623](https://pubmed.ncbi.nlm.nih.gov/24687623/)
13. Thepen T, Rooijen NV, Krall G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. *J. Exp. Med*. 1989 Aug; 170: 499–509.
14. Jansen HM. The role of alveolar macrophages and dendritic cells in allergic airway sensitization. *Allergy*. 1996 May; 51(5): 279–92. PMID: [8836331](https://pubmed.ncbi.nlm.nih.gov/8836331/)
15. Balhara J, Gounni AS. The alveolar macrophages in asthma: a double-edged sword. *Mucosal Immunology* 2012 Nov; 5(6): 605–9. doi: [10.1038/mi.2012.74](https://doi.org/10.1038/mi.2012.74) PMID: [22910216](https://pubmed.ncbi.nlm.nih.gov/22910216/)
16. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. *J Exp Med*. 1989 Aug 1; 170(2): 499–509. PMID: [2526847](https://pubmed.ncbi.nlm.nih.gov/2526847/)
17. Barnes PJ. Alveolar macrophages in chronic obstructive pulmonary disease (COPD), *Cell Mol Biol (Noisy-le-grand)*. 2004; 50.
18. Woodruff PG, Koth LL, Yang YH, Rodriguez MW, Favoreto S, Dolganov GM, Paquet AC, Erle DJ. A distinctive alveolar macrophage activation state induced by cigarette smoking. *Am J Respir Crit Care Med*. 2005 Dec 1; 172(11): 1383–92. doi: [10.1164/rccm.200505-686OC](https://doi.org/10.1164/rccm.200505-686OC) PMID: [16166618](https://pubmed.ncbi.nlm.nih.gov/16166618/)
19. Pribul PK, Harker J, Wang B, Wang H, Tregoning JS, Schwarze J, Openshaw PJ. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. *J Virol*. 2008 May; 82(9): 4441–8. doi: [10.1128/JVI.02541-07](https://doi.org/10.1128/JVI.02541-07) PMID: [18287232](https://pubmed.ncbi.nlm.nih.gov/18287232/)
20. Speck Nancy A. & Gilliland D. Gary. Core-binding factors in haematopoiesis and leukaemia. *Nature Reviews Cancer* 2002 July (2): 502–513.
21. de Bruijn MF, Speck NA. Core-binding factors in hematopoiesis and immune function. *Oncogene*. 2004 May (24): 4238–48. doi: [10.1038/sj.onc.1207763](https://doi.org/10.1038/sj.onc.1207763) PMID: [15156179](https://pubmed.ncbi.nlm.nih.gov/15156179/)
22. Borregaard N, Theilgaard-Mönch K, Sørensen OE, Cowland JB. Regulation of human neutrophil granule protein expression. *Curr Opin Hematol*. 2001 Jan; 8(1): 23–7. PMID: [11138622](https://pubmed.ncbi.nlm.nih.gov/11138622/)
23. Kirby AC, Raynes JG, Kaye PM. CD11b regulates recruitment of alveolar macrophages but not pulmonary dendritic cells after pneumococcal challenge. *J Infect Dis*. 2006 Jan 15; 193(2): 205–13. doi: [10.1086/498874](https://doi.org/10.1086/498874) PMID: [16362884](https://pubmed.ncbi.nlm.nih.gov/16362884/)
24. Kopf M, Schneider C, Nobs S. P.. The development and function of lung- resident macrophages and dendritic cells. *Nature Immunology*. 2015 (16), 36–44.
25. Tate MD, Brooks AG, Reading PC. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. *Respir Res*. 2008 Aug 1; 9:57. doi: [10.1186/1465-9921-9-57](https://doi.org/10.1186/1465-9921-9-57) PMID: [18671884](https://pubmed.ncbi.nlm.nih.gov/18671884/)



26. Hufford MM, Kim TS, Sun J, Braciale TJ. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. *J Exp Med*. 2011 Jan 17; 208(1): 167–80. doi: [10.1084/jem.20101850](https://doi.org/10.1084/jem.20101850) PMID: [21187318](https://pubmed.ncbi.nlm.nih.gov/21187318/)
27. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, García-Sastre A. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. *Proc Natl Acad Sci U S A*. 2010 June 22; 107(25): 11531–11536. doi: [10.1073/pnas.0914994107](https://doi.org/10.1073/pnas.0914994107) PMID: [20534532](https://pubmed.ncbi.nlm.nih.gov/20534532/)
28. Rosenberger CM, Podyminogin RL, Askovich PS, Navarro G, Kaiser SM, Sanders CJ, McClaren JL, Tam VC, Dash P, Noonan JG, Jones BG, Surman SL, Peschon JJ, Diercks AH, Hurwitz JL, Doherty PC, Thomas PG, Aderem A. Characterization of innate responses to influenza virus infection in a novel lung type I epithelial cell model. *J Gen Virol*. 2014 Feb; 95(Pt 2): 350–62. doi: [10.1099/vir.0.058438-0](https://doi.org/10.1099/vir.0.058438-0) PMID: [24243730](https://pubmed.ncbi.nlm.nih.gov/24243730/)
29. McElroy MC, Kasper M. The use of alveolar epithelial type I cell-selective markers to investigate lung injury and repair. *Eur Respir J*. 2004 Oct; 24(4): 664–73. doi: [10.1183/09031936.04.00096003](https://doi.org/10.1183/09031936.04.00096003) PMID: [15459148](https://pubmed.ncbi.nlm.nih.gov/15459148/)
30. Yamamoto K, Ferrari JD, Cao Y, Ramirez MI, Jones MR, Quinton LJ, Mizgerd JP. Type I alveolar epithelial cells mount innate immune responses during pneumococcal pneumonia. *J Immunol*. 2012 Sep 1; 189(5): 2450–9. doi: [10.4049/jimmunol.1200634](https://doi.org/10.4049/jimmunol.1200634) PMID: [22844121](https://pubmed.ncbi.nlm.nih.gov/22844121/)
31. Chuquimia OD, Petursdottir DH, Rahman MJ, Hartl K, Singh M, Fernández C. The role of alveolar epithelial cells in initiating and shaping pulmonary immune responses: communication between innate and adaptive immune systems. *PLoS One*. 2012; 7(2): e32125. doi: [10.1371/journal.pone.0032125](https://doi.org/10.1371/journal.pone.0032125) PMID: [22393384](https://pubmed.ncbi.nlm.nih.gov/22393384/)
32. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? *Nat Rev Immunol*. 2014 Nov; 14(11):719–30. doi: [10.1038/nri3754](https://doi.org/10.1038/nri3754) PMID: [25324123](https://pubmed.ncbi.nlm.nih.gov/25324123/)
33. Debbabi H, Ghosh S, Kamath AB, Alt J, Demello DE, Dunsmore S, Behar SM. Primary type II alveolar epithelial cells present microbial antigens to antigen-specific CD4+ T cells. *Am J Physiol Lung Cell Mol Physiol*. 2005 Aug; 289(2): L274–9. doi: [10.1152/ajplung.00004.2005](https://doi.org/10.1152/ajplung.00004.2005) PMID: [15833765](https://pubmed.ncbi.nlm.nih.gov/15833765/)
34. Stegemann-Koniszewski S, Jeron A, Gereke M, Geffers R, Kröger A, Gunzer M, Bruder D. Alveolar Type II Epithelial Cells Contribute to the Anti-Influenza A Virus Response in the Lung by Integrating Pathogen- and Microenvironment-Derived Signals. *MBio*. 2016 May 3; 7(3). pii: e00276–16. doi: [10.1128/mBio.00276-16](https://doi.org/10.1128/mBio.00276-16) PMID: [27143386](https://pubmed.ncbi.nlm.nih.gov/27143386/)
35. Cho HC, Lai CY, Shao LE, Yu J. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma. *Cancer Res*. 2011 Dec 1; 71(23): 7250–8. doi: [10.1158/0008-5472.CAN-11-0903](https://doi.org/10.1158/0008-5472.CAN-11-0903) PMID: [22088965](https://pubmed.ncbi.nlm.nih.gov/22088965/)
36. Kumagai Y, Takeuchi O, Kato H, Kumar H, Matsui K, Morii E, Aozasa K, Kawai T, Akira S. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. *Immunity*. 2007 Aug; 27(2): 240–52. doi: [10.1016/j.immuni.2007.07.013](https://doi.org/10.1016/j.immuni.2007.07.013) PMID: [17723216](https://pubmed.ncbi.nlm.nih.gov/17723216/)
37. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. *Nature Protoc*. 2009; 4(1): 44–57.
38. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res*. 2009; 37(1): 1–13. doi: [10.1093/nar/gkn923](https://doi.org/10.1093/nar/gkn923) PMID: [19033363](https://pubmed.ncbi.nlm.nih.gov/19033363/)
39. Tam VC, Quehenberger O, Oshansky CM, Suen R, Armando AM, Treuting PM, Thomas PG, Dennis EA, Aderem A. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. *Cell*. 2013 Jul 3; 154(1): 213–27. doi: [10.1016/j.cell.2013.05.052](https://doi.org/10.1016/j.cell.2013.05.052) PMID: [23827684](https://pubmed.ncbi.nlm.nih.gov/23827684/)
40. Oguin TH, Sharma S, Stuart AD, Duan S, Scott SA, Jones CK, Daniels JS, Lindsley CW, Thomas PG, Brown HA. Phospholipase D facilitates efficient entry of influenza virus, allowing escape from innate immune inhibition. *J Biol Chem*. 2014 Sep 12; 289(37): 25405–17. doi: [10.1074/jbc.M114.558817](https://doi.org/10.1074/jbc.M114.558817) PMID: [25065577](https://pubmed.ncbi.nlm.nih.gov/25065577/)
41. König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Origoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, García-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. Human host factors required for influenza virus replication. *Nature*. 2010 Feb 11; 463(7282): 813–7. doi: [10.1038/nature08699](https://doi.org/10.1038/nature08699) PMID: [20027183](https://pubmed.ncbi.nlm.nih.gov/20027183/)
42. Fujioka Y, Tsuda M, Nanbo A, Hattori T, Sasaki J, Sasaki T, Miyazaki T, Ohba Y. A Ca<sup>2+</sup> Dependent signaling circuit regulates influenza A virus internalization and infection. *Nature Communications*. 2013 Nov 14; 4: 2763. doi: [10.1038/ncomms3763](https://doi.org/10.1038/ncomms3763) PMID: [24434940](https://pubmed.ncbi.nlm.nih.gov/24434940/)
43. Rådmark O. and Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. *The Journal of Biological Chemistry*. 2002 Feb 8; 277, 4374–4379.

44. Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, Libner R, Davi G, Procopio A. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. *FASEB J*. 2001 Nov; 15(13): 2326–36. doi: [10.1096/fj.01-0150com](https://doi.org/10.1096/fj.01-0150com) PMID: [11689458](https://pubmed.ncbi.nlm.nih.gov/11689458/)
45. Cortese JF, Spannhake EW, Eisinger W, Potter JJ, Yang VW. The 5-lipoxygenase pathway in cultured human intestinal epithelial cells. *Prostaglandins*. 1995 Mar; 49(3): 155–66. PMID: [7652184](https://pubmed.ncbi.nlm.nih.gov/7652184/)
46. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. *Am J Respir Crit Care Med*. 1998 Jan; 157(1): 219–29. doi: [10.1164/ajrccm.157.1.9704003](https://doi.org/10.1164/ajrccm.157.1.9704003) PMID: [9445303](https://pubmed.ncbi.nlm.nih.gov/9445303/)
47. Manev H, Uz T, Sugaya K, Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. *FASEB J*. 2000 Jul; 14(10): 1464–9. PMID: [10877840](https://pubmed.ncbi.nlm.nih.gov/10877840/)
48. Uhl J, Klan N, Rose M, Entian KD, Werz O, Steinhilber D. The 5-lipoxygenase promoter is regulated by DNA methylation. *J Biol Chem*. 2002 Feb 8; 277(6): 4374–9. doi: [10.1074/jbc.M107665200](https://doi.org/10.1074/jbc.M107665200) PMID: [11706027](https://pubmed.ncbi.nlm.nih.gov/11706027/)
49. Zhang Z, Chen CQ, Manev H. DNA methylation as an epigenetic regulator of neural 5-lipoxygenase expression: evidence in human NT2 and NT2-N cells. *J Neurochem*. 2004 Mar; 88(6): 1424–30. PMID: [15009643](https://pubmed.ncbi.nlm.nih.gov/15009643/)
50. Imbesi M, Dzitoyeva S, Ng LW, Manev H. 5-Lipoxygenase and epigenetic DNA methylation in aging cultures of cerebellar granule cells. *Neuroscience*. 2009 Dec 29; 164(4): 1531–7. doi: [10.1016/j.neuroscience.2009.09.039](https://doi.org/10.1016/j.neuroscience.2009.09.039) PMID: [19778587](https://pubmed.ncbi.nlm.nih.gov/19778587/)
51. Tighe S, Held MA. Isolation of total RNA from transgenic mouse melanoma subsets using fluorescence-activated cell sorting. *Methods Mol Biol*. 2010; 632:27–44. doi: [10.1007/978-1-60761-663-4\\_2](https://doi.org/10.1007/978-1-60761-663-4_2) PMID: [20217569](https://pubmed.ncbi.nlm.nih.gov/20217569/)
52. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nature Protocols* (2012); 7:562–578. doi: [10.1038/nprot.2012.016](https://doi.org/10.1038/nprot.2012.016) PMID: [22383036](https://pubmed.ncbi.nlm.nih.gov/22383036/)